Search

Your search keyword '"Pusic, Iskra"' showing total 441 results
Start Over Author "Pusic, Iskra"
441 results on '"Pusic, Iskra"'

2. Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002

Author

Meyers, Gabrielle, Hamadani, Mehdi, Martens, Michael, Ali, Haris, Chevallier, Patrice, Choe, Hannah, Harris, Andrew C., Holler, Ernst, van Hooren, Eric, Klaassen, Willem, Leifer, Eric, van Oosterhout, Ypke, Perez, Lia, Pusic, Iskra, Stelljes, Matthias, van der Velden, Walter, Ammatuna, Emanuele, Beauvais, David, Cornillon, Jérôme, Maziarz, Richard T., Schetelig, Johannes, Romeril, Jennifer, MacMillan, Margaret L., Levine, John E., and Socié, Gérard

Published
2023
Full Text
View/download PDF

4. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans

Author

Alsoussi, Wafaa B., Malladi, Sameer Kumar, Zhou, Julian Q., Liu, Zhuoming, Ying, Baoling, Kim, Wooseob, Schmitz, Aaron J., Lei, Tingting, Horvath, Stephen C., Sturtz, Alexandria J., McIntire, Katherine M., Evavold, Birk, Han, Fangjie, Scheaffer, Suzanne M., Fox, Isabella F., Mirza, Senaa F., Parra-Rodriguez, Luis, Nachbagauer, Raffael, Nestorova, Biliana, Chalkias, Spyros, Farnsworth, Christopher W., Klebert, Michael K., Pusic, Iskra, Strnad, Benjamin S., Middleton, William D., Teefey, Sharlene A., Whelan, Sean P. J., Diamond, Michael S., Paris, Robert, O’Halloran, Jane A., Presti, Rachel M., Turner, Jackson S., and Ellebedy, Ali H.

Published
2023
Full Text
View/download PDF

5. Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia

Author

Desai, Pinkal M, Brown, Janice, Gill, Saar, Solh, Melham M, Akard, Luke P, Hsu, Jack W, Ustun, Celalettin, Andreadis, Charalambos, Frankfurt, Olga, Foran, James M, Lister, John, Schiller, Gary J, Wieduwilt, Matthew J, Pagel, John M, Stiff, Patrick J, Liu, Delong, Khan, Irum, Stock, Wendy, Kambhampati, Suman, Tallman, Martin S, Morris, Lawrence, Edwards, John, Pusic, Iskra, Kantarjian, Hagop M, Mamelok, Richard, Wong, Alicia, Van Syoc, Rodney, Kellerman, Lois, Panuganti, Swapna, Mandalam, Ramkumar, Abboud, Camille N, and Ravandi, Farhad

Subjects
Clinical Trials and Supportive Activities, Rare Diseases, Hematology, Clinical Research, Infectious Diseases, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Adult, Aged, Antifungal Agents, Female, Granulocyte Colony-Stimulating Factor, Humans, Induction Chemotherapy, Leukemia, Myeloid, Acute, Male, Middle Aged, Myeloid Progenitor Cells, Neutrophils, Prospective Studies, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeStandard cytotoxic induction chemotherapy for acute myeloid leukemia (AML) results in prolonged neutropenia and risk of infection. Romyelocel-L is a universal, allogeneic myeloid progenitor cell product being studied to reduce infection during induction chemotherapy.Patients and methodsOne hundred sixty-three patients with de novo AML (age ≥ 55 years) receiving induction chemotherapy were randomly assigned on day 0 (d0), of whom 120 were evaluable. Subjects received either romyelocel-L infusion on d9 with granulocyte colony-stimulating factor (G-CSF) starting daily d14 (treatment group) or G-CSF daily alone on d14 (control) until absolute neutrophil count recovery to 500/µL. End points included days in febrile episode, microbiologically defined infections, clinically diagnosed infection, and days in hospital.ResultsMean days in febrile episode was shorter in the treatment arm from d15 through d28 (2.36 v 3.90; P = .02). Similarly, a trend toward decreased microbiologically defined infections and clinically diagnosed infection in the treatment arm was observed from d9 to d28 (35.6% v 47.5%; P = .09), reaching a statistically significant difference from d15 to d28 (6.8% v 27.9%; P = .002). Because of this, antibacterial or antifungal use for treatment of an infection was significantly less in the treatment group (d9-d28: 44.1% v 63.9%; P = .01). Significantly fewer patients in the treatment arm received empiric antifungals from d9 tod28 (42.4% v 63.9%; P = .02) and d15-d28 (42.4% v 62.3%; P = .02). Patients in the treatment arm also had 3.2 fewer hospital days compared with control (25.5 v 28.7; P = .001). Remission rates and days to absolute neutrophil count recovery were similar in the two groups. No patients in the romyelocel-L plus G-CSF group died because of infection compared with two patients in the control arm. No graft-versus-host disease was observed.ConclusionSubjects receiving romyelocel-L showed a decreased incidence of infections, antimicrobial use, and hospitalization, suggesting that romyelocel-L may provide a new option to reduce infections in patients with AML undergoing induction therapy.

Published
2021

6. Germinal centre-driven maturation of B cell response to mRNA vaccination

Author

Kim, Wooseob, Zhou, Julian Q., Horvath, Stephen C., Schmitz, Aaron J., Sturtz, Alexandria J., Lei, Tingting, Liu, Zhuoming, Kalaidina, Elizaveta, Thapa, Mahima, Alsoussi, Wafaa B., Haile, Alem, Klebert, Michael K., Suessen, Teresa, Parra-Rodriguez, Luis, Mudd, Philip A., Whelan, Sean P. J., Middleton, William D., Teefey, Sharlene A., Pusic, Iskra, O’Halloran, Jane A., Presti, Rachel M., Turner, Jackson S., and Ellebedy, Ali H.

Published
2022
Full Text
View/download PDF

7. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

Author

Bolaños-Meade, Javier, Reshef, Ran, Fraser, Raphael, Fei, Mingwei, Abhyankar, Sunil, Al-Kadhimi, Zaid, Alousi, Amin M, Antin, Joseph H, Arai, Sally, Bickett, Kate, Chen, Yi-Bin, Damon, Lloyd E, Efebera, Yvonne A, Geller, Nancy L, Giralt, Sergio A, Hari, Parameswaran, Holtan, Shernan G, Horowitz, Mary M, Jacobsohn, David A, Jones, Richard J, Liesveld, Jane L, Logan, Brent R, MacMillan, Margaret L, Mielcarek, Marco, Noel, Pierre, Pidala, Joseph, Porter, David L, Pusic, Iskra, Sobecks, Ronald, Solomon, Scott R, Weisdorf, Daniel J, Wu, Juan, Pasquini, Marcelo C, and Koreth, John

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Trials and Supportive Activities, Hematology, Transplantation, Cancer, Rare Diseases, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Aged, Bortezomib, Cyclophosphamide, Drug Interactions, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Male, Maraviroc, Methotrexate, Middle Aged, Mycophenolic Acid, Tacrolimus, Transplantation Conditioning, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

BackgroundPrevention of graft-versus-host disease (GvHD) without malignant relapse is the overall goal of allogeneic haemopoietic cell transplantation (HCT). We aimed to evaluate regimens using either maraviroc, bortezomib, or post-transplantation cyclophosphamide for GvHD prophylaxis compared with controls receiving the combination of tacrolimus and methotrexate using a novel composite primary endpoint to identify the most promising intervention to be further tested in a phase 3 trial.MethodsIn this prospective multicentre phase 2 trial, adult patients aged 18-75 years who received reduced-intensity conditioning HCT were randomly assigned (1:1:1) by random block sizes to tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide (cyclophosphamide 50 mg/kg on days 3 and 4, followed by tacrolimus starting on day 5 and mycophenolate mofetil starting on day 5 at 15 mg/kg three times daily not to exceed 1 g from day 5 to day 35); tacrolimus, methotrexate, and bortezomib (bortezomib 1·3 mg/m2 intravenously on days 1, 4, and 7 after HCT); or tacrolimus, methotrexate, and maraviroc (maraviroc 300 mg orally twice daily from day -3 to day 30 after HCT). Methotrexate was administered as a 15 mg/m2 intravenous bolus on day 1 and 10 mg/m2 intravenous bolus on days 3, 6, and 11 after HCT; tacrolimus was given intravenously at a dose of 0·05 mg/kg twice daily (or oral equivalent) starting on day -3 (except the post-transplantation cyclophosphamide, as indicated), with a target level of 5-15 ng/mL. Tacrolimus was continued at least until day 90 and was tapered off by day 180. Each study group was compared separately to a contemporary non-randomised prospective cohort of patients (control group) who fulfilled the same eligibility criteria as the trial, but who were treated with tacrolimus and methotrexate at centres not participating in the trial. The primary endpoint (GvHD-free, relapse-free survival [GRFS]) was defined as the time from HCT to onset of grade 3-4 acute GvHD, chronic GvHD requiring systemic immunosuppression, disease relapse, or death. The study was analysed by modified intention to treat. The study is closed to accrual and this is the planned analysis. This trial is registered with ClinicalTrials.gov, number NCT02208037.FindingsBetween Nov 17, 2014, and May 18, 2016, 273 patients from 31 US centres were randomly assigned to the three study arms: 89 to tacrolimus, methotrexate, and bortezomib; 92 to tacrolimus, methotrexate, and maraviroc; 92 to tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; and six were excluded. Between Aug 1, 2014, and Sept 14, 2016, 224 controls received tacrolimus and methotrexate. Controls were generally well matched except for more frequent comorbidities than the intervention groups and a different distribution of types of conditioning regimens used. Compared with controls, the hazard ratio for GRFS was 0·72 (90% CI 0·54-0·94; p=0·044) for tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide, 0·98 (0·76-1·27; p=0·92) for tacrolimus, methotrexate, and bortezomib, and 1·10 (0·86-1·41; p=0·49) for tacrolimus, methotrexate, and maraviroc. 238 patients experienced grade 3 or 4 toxicities: 12 (13%) had grade 3 and 67 (73%) grade 4 events with tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; ten (11%) had grade 3 and 68 (76%) had grade 4 events with tacrolimus, methotrexate, and bortezomib; and 18 (20%) had grade 3 and 63 (68%) had grade 4 events with tacrolimus, methotrexate, and maraviroc. The most common toxicities were haematological (77 [84%] for tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; 73 [82%] for tacrolimus, methotrexate, and bortezomib; and 78 [85%] for tacrolimus, methotrexate, and maraviroc) and cardiac (43 [47%], 44 [49%], and 43 [47%], respectively).InterpretationTacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide was the most promising intervention, yielding the best GRFS; this regimen is thus being prospectively compared with tacrolimus and methotrexate in a phase 3 randomised trial.FundingUS National Health, Lung, and Blood Institute; National Cancer Institute; National Institute of Allergy and Infectious Disease; and Millennium Pharmaceuticals.

Published
2019

9. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Author

Shah, Neil P., primary, Bhatia, Ravi, additional, Altman, Jessica K., additional, Amaya, Maria, additional, Begna, Kebede H., additional, Berman, Ellin, additional, Chan, Onyee, additional, Clements, Joan, additional, Collins, Robert H., additional, Curtin, Peter T., additional, DeAngelo, Daniel J., additional, Drazer, Michael, additional, Maness, Lori, additional, Metheny, Leland, additional, Mohan, Sanjay, additional, Moore, Joseph O., additional, Oehler, Vivian, additional, Pratz, Keith, additional, Pusic, Iskra, additional, Rose, Michal G., additional, Shomali, William, additional, Smith, B. Douglas, additional, Styler, Michael, additional, Talpaz, Moshe, additional, Tanaka, Tiffany N., additional, Tantravahi, Srinivas, additional, Thompson, James, additional, Tsai, Steven, additional, Vaughn, Jennifer, additional, Welborn, Jeanna, additional, Yang, David T., additional, Sundar, Hema, additional, and Gregory, Kristina, additional

Published
2024
Full Text
View/download PDF

11. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

Author

Turner, Jackson S., Kim, Wooseob, Kalaidina, Elizaveta, Goss, Charles W., Rauseo, Adriana M., Schmitz, Aaron J., Hansen, Lena, Haile, Alem, Klebert, Michael K., Pusic, Iskra, O'Halloran, Jane A., and Presti, Rachel M.

Subjects
Bone marrow -- Health aspects, Plasma cells -- Health aspects, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Long-lived bone marrow plasma cells (BMPCs) are a persistent and essential source of protective antibodies.sup.1-7. Individuals who have recovered from COVID-19 have a substantially lower risk of reinfection with SARS-CoV-2.sup.8-10. Nonetheless, it has been reported that levels of anti-SARS-CoV-2 serum antibodies decrease rapidly in the first few months after infection, raising concerns that long-lived BMPCs may not be generated and humoral immunity against SARS-CoV-2 may be short-lived.sup.11-13. Here we show that in convalescent individuals who had experienced mild SARS-CoV-2 infections (n = 77), levels of serum anti-SARS-CoV-2 spike protein (S) antibodies declined rapidly in the first 4 months after infection and then more gradually over the following 7 months, remaining detectable at least 11 months after infection. Anti-S antibody titres correlated with the frequency of S-specific plasma cells in bone marrow aspirates from 18 individuals who had recovered from COVID-19 at 7 to 8 months after infection. S-specific BMPCs were not detected in aspirates from 11 healthy individuals with no history of SARS-CoV-2 infection. We show that S-binding BMPCs are quiescent, which suggests that they are part of a stable compartment. Consistently, circulating resting memory B cells directed against SARS-CoV-2 S were detected in the convalescent individuals. Overall, our results indicate that mild infection with SARS-CoV-2 induces robust antigen-specific, long-lived humoral immune memory in humans. SARS-CoV-2 infection induces long-lived bone marrow plasma cells that correlate with anti-SARS-CoV-2 spike protein antibody titres in individuals who have recovered from COVID-19., Author(s): Jackson S. Turner [sup.1] , Wooseob Kim [sup.1] , Elizaveta Kalaidina [sup.2] , Charles W. Goss [sup.3] , Adriana M. Rauseo [sup.4] , Aaron J. Schmitz [sup.1] , Lena [...]

Published
2021
Full Text
View/download PDF

12. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy

Author

Kharfan-Dabaja, Mohamed A., Kumar, Ambuj, Ayala, Ernesto, Aljurf, Mahmoud, Nishihori, Taiga, Marsh, Rebecca, Burroughs, Lauri M., Majhail, Navneet, Al-Homsi, A. Samer, Al-Kadhimi, Zaid S., Bar, Merav, Bertaina, Alice, Boelens, Jaap J., Champlin, Richard, Chaudhury, Sonali, DeFilipp, Zachariah, Dholaria, Bhagirathbhai, El-Jawahri, Areej, Fanning, Suzanne, Fraint, Ellen, Gergis, Usama, Giralt, Sergio, Hamilton, Betty K., Hashmi, Shahrukh K., Horn, Biljana, Inamoto, Yoshihiro, Jacobsohn, David A, Jain, Tania, Johnston, Laura, Kanate, Abraham S., Kansagra, Ankit, Kassim, Adetola, Kean, Leslie S., Kitko, Carrie L., Knight-Perry, Jessica, Kurtzberg, Joanne, Liu, Hien, MacMillan, Margaret L., Mahmoudjafari, Zahra, Mielcarek, Marco, Mohty, Mohamad, Nagler, Arnon, Nemecek, Eneida, Olson, Timothy S., Oran, Betul, Perales, Miguel-Angel, Prockop, Susan E., Pulsipher, Michael A., Pusic, Iskra, Riches, Marcie L., Rodriguez, Cesar, Romee, Rizwan, Rondon, Gabriela, Saad, Ayman, Shah, Nina, Shaw, Peter J., Shenoy, Shalini, Sierra, Jorge, Talano, Julie, Verneris, Michael R., Veys, Paul, Wagner, John E., Savani, Bipin N., Hamadani, Mehdi, and Carpenter, Paul A.

Published
2021
Full Text
View/download PDF

13. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report

Author

Williams, Kirsten M., Inamoto, Yoshihiro, Im, Annie, Hamilton, Betty, Koreth, John, Arora, Mukta, Pusic, Iskra, Mays, Jacqueline W., Carpenter, Paul A., Luznik, Leo, Reddy, Pavan, Ritz, Jerome, Greinix, Hildegard, Paczesny, Sophie, Blazar, Bruce R., Pidala, Joseph, Cutler, Corey, Wolff, Daniel, Schultz, Kirk R., Pavletic, Steven Z., Lee, Stephanie J., Martin, Paul J., Socie, Gerard, and Sarantopoulos, Stefanie

Published
2021
Full Text
View/download PDF

15. A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease

Author

Curtis, Lauren M., Ostojic, Alen, Venzon, David J., Holtzman, Noa G., Pirsl, Filip, Kuzmina, Zoya J., Baird, Kristin, Rose, Jeremy J., Cowen, Edward W., Mays, Jacqueline W., Mitchell, Sandra A., Parsons-Wandell, Laura, Joe, Galen O., Comis, Leora E., Berger, Ann, Pusic, Iskra, Peer, Cody J., Figg, William D., Cao, Liang, Gale, Robert Peter, Hakim, Frances T., and Pavletic, Steven Z.

Published
2021
Full Text
View/download PDF

18. CML and the WHO: Why?

Author

Berman, Ellin, primary, Shah, Neil P., additional, Deninger, Michael, additional, Altman, Jessica K., additional, Amaya, Maria, additional, Begna, Kebede, additional, Bhatia, Ravi, additional, Chan, Onyee, additional, Collins, Robert, additional, Curtin, Peter, additional, DeAngelo, Daniel J., additional, Drazer, Michael, additional, Maness, Lori, additional, Metheny, Leland, additional, Mohan, Sanjay, additional, Moore, Joseph, additional, Oehler, Vivian, additional, Pratz, Keith, additional, Pusic, Iskra, additional, Rose, Michal, additional, Shomali, William, additional, Smith, B. Douglas, additional, Styler, Michael, additional, Sweet, Kendra, additional, Talpaz, Moshe, additional, Tanaka, Tiffany, additional, Tantravahi, Srinivas, additional, Tsai, Steven, additional, Vaughn, Jennifer, additional, Welborn, Jeanna, additional, Yang, David, additional, Mauro, Michael, additional, Cortes, Jorge, additional, Radich, Jerald, additional, and Druker, Brian, additional

Published
2023
Full Text
View/download PDF

20. 45. Clonal hematopoiesis in childhood cancer survivors

Author

Chan, Irenaeus, primary, Friedman, Danielle, additional, Moskowitz, Chaya, additional, Li, Shanita, additional, Turner, Kimberly, additional, Liu, Jie, additional, Bouvier, Nancy, additional, Walsh, Michael, additional, Spitzer, Barbara, additional, Kung, Andrew, additional, Berger, Michael, additional, Cooper, Megan, additional, Pusic, Iskra, additional, Uy, Geoffrey, additional, Link, Daniel, additional, Druley, Todd, additional, Diaz, Luis, additional, Levine, Ross, additional, Shukla, Neerav, additional, and Bolton, Kelly, additional

Published
2023
Full Text
View/download PDF

23. CML and the WHO: Why?

Author

Berman, Ellin, Shah, Neil P., Deninger, Michael, Altman, Jessica K., Amaya, Maria, Begna, Kebede, Bhatia, Ravi, Chan, Onyee, Collins, Robert, Curtin, Peter, DeAngelo, Daniel J., Drazer, Michael, Maness, Lori, Metheny, Leland, Mohan, Sanjay, Moore, Joseph, Oehler, Vivian, Pratz, Keith, Pusic, Iskra, and Rose, Michal

Published
2024
Full Text
View/download PDF

24. Clonal hematopoiesis in survivors of childhood cancer

Author

Novetsky Friedman, Danielle, primary, Chan, Irenaeus C. C., additional, Moskowitz, Chaya S., additional, Li, Shanita, additional, Turner, Kimberly, additional, Liu, Jie, additional, Bouvier, Nancy, additional, Walsh, Michael F., additional, Spitzer, Barbara, additional, Kung, Andrew L., additional, Berger, Michael, additional, Cooper, Megan A., additional, Pusic, Iskra, additional, Uy, Geoffrey, additional, Link, Daniel, additional, Druley, Todd E., additional, Diaz, Luis A., additional, Levine, Ross L., additional, Shukla, Neerav, additional, and Bolton, Kelly L., additional

Published
2023
Full Text
View/download PDF

27. Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia

Author

Barnell, Erica K., Newcomer, Kenneth F., Skidmore, Zachary L., Krysiak, Kilannin, Anderson, Sydney R., Wartman, Lukas D., Oh, Stephen T., Welch, John S., Stockerl-Goldstein, Keith E., Vij, Ravi, Cashen, Amanda F., Pusic, Iskra, Westervelt, Peter, Abboud, Camille N., Ghobadi, Armin, Uy, Geoffrey L., Schroeder, Mark A., Dipersio, John F., Politi, Mary C., Spencer, David H., Duncavage, Eric J., Ley, Timothy J., Griffith, Malachi, Jacoby, Meagan A., and Griffith, Obi L.

Published
2021
Full Text
View/download PDF

29. Patient-reported treatment response in chronic graft-versus-host disease

Author

Im, Annie, primary, Pusic, Iskra, additional, Onstad, Lynn, additional, Kitko, Carrie L., additional, Hamilton, Betty K., additional, Alousi, Amin M., additional, Flowers, Mary E., additional, Sarantopoulos, Stefanie, additional, Carpenter, Paul, additional, White, Jennifer, additional, Arai, Sally, additional, El Jurdi, Najla, additional, Chen, George, additional, Cutler, Corey, additional, Lee, Stephanie, additional, and Pidala, Joseph, additional

Published
2023
Full Text
View/download PDF

30. Abstract 4342: Predictive precision medicine platform accurately predicts individual patient response to AML treatments to maximize outcomes

Author

Jacoby, Meagan A., primary, Welch, John S., additional, Westervelt, Peter, additional, Christopher, Matthew, additional, Uy, Geoffrey L., additional, Vij, Ravi, additional, Stockerl-Goldstein, Keith E., additional, Kahl, Brad S., additional, Pusic, Iskra, additional, DiPersio, John F., additional, Schroeder, Mark A., additional, Kim, Miriam Y., additional, Fehniger, Todd A., additional, Ghobadi, Armin, additional, Gu, Christine J., additional, Anderson, Wade, additional, Vanderlaag, Kathryn, additional, Ali, Kamran, additional, Pataki, Camille, additional, and Lacher, Markus D., additional

Published
2023
Full Text
View/download PDF

31. Data from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Author

Berrien-Elliott, Melissa M., primary, Cashen, Amanda F., primary, Cubitt, Celia C., primary, Neal, Carly C., primary, Wong, Pamela, primary, Wagner, Julia A., primary, Foster, Mark, primary, Schappe, Timothy, primary, Desai, Sweta, primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foltz, Jennifer A., primary, Cooper, Matthew L., primary, Jaeger, Natalia, primary, Srivatsan, Sridhar Nonavinkere, primary, Gao, Feng, primary, Romee, Rizwan, primary, Abboud, Camille N., primary, Uy, Geoffrey L., primary, Westervelt, Peter, primary, Jacoby, Meagan A., primary, Pusic, Iskra, primary, Stockerl-Goldstein, Keith E., primary, Schroeder, Mark A., primary, DiPersio, John, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Tables from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Author

Berrien-Elliott, Melissa M., primary, Cashen, Amanda F., primary, Cubitt, Celia C., primary, Neal, Carly C., primary, Wong, Pamela, primary, Wagner, Julia A., primary, Foster, Mark, primary, Schappe, Timothy, primary, Desai, Sweta, primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foltz, Jennifer A., primary, Cooper, Matthew L., primary, Jaeger, Natalia, primary, Srivatsan, Sridhar Nonavinkere, primary, Gao, Feng, primary, Romee, Rizwan, primary, Abboud, Camille N., primary, Uy, Geoffrey L., primary, Westervelt, Peter, primary, Jacoby, Meagan A., primary, Pusic, Iskra, primary, Stockerl-Goldstein, Keith E., primary, Schroeder, Mark A., primary, DiPersio, John, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Methods from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Author

Berrien-Elliott, Melissa M., primary, Cashen, Amanda F., primary, Cubitt, Celia C., primary, Neal, Carly C., primary, Wong, Pamela, primary, Wagner, Julia A., primary, Foster, Mark, primary, Schappe, Timothy, primary, Desai, Sweta, primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foltz, Jennifer A., primary, Cooper, Matthew L., primary, Jaeger, Natalia, primary, Srivatsan, Sridhar Nonavinkere, primary, Gao, Feng, primary, Romee, Rizwan, primary, Abboud, Camille N., primary, Uy, Geoffrey L., primary, Westervelt, Peter, primary, Jacoby, Meagan A., primary, Pusic, Iskra, primary, Stockerl-Goldstein, Keith E., primary, Schroeder, Mark A., primary, DiPersio, John, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figures from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

Author

Berrien-Elliott, Melissa M., primary, Cashen, Amanda F., primary, Cubitt, Celia C., primary, Neal, Carly C., primary, Wong, Pamela, primary, Wagner, Julia A., primary, Foster, Mark, primary, Schappe, Timothy, primary, Desai, Sweta, primary, McClain, Ethan, primary, Becker-Hapak, Michelle, primary, Foltz, Jennifer A., primary, Cooper, Matthew L., primary, Jaeger, Natalia, primary, Srivatsan, Sridhar Nonavinkere, primary, Gao, Feng, primary, Romee, Rizwan, primary, Abboud, Camille N., primary, Uy, Geoffrey L., primary, Westervelt, Peter, primary, Jacoby, Meagan A., primary, Pusic, Iskra, primary, Stockerl-Goldstein, Keith E., primary, Schroeder, Mark A., primary, DiPersio, John, primary, and Fehniger, Todd A., primary

Published
2023
Full Text
View/download PDF

36. Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors

Author

Holtan, Shernan G., Khera, Nandita, Levine, John E., Chai, Xiaoyu, Storer, Barry, Liu, Hien D., Inamoto, Yoshihiro, Chen, George L., Mayer, Sebastian, Arora, Mukta, Palmer, Jeanne, Flowers, Mary E.D., Cutler, Corey S., Lukez, Alexander, Arai, Sally, Lazaryan, Aleksandr, Newell, Laura F., Krupski, Christa, Jagasia, Madan H., Pusic, Iskra, Wood, William, Renteria, Anne S., Yanik, Gregory, Hogan, William J., Hexner, Elizabeth, Ayuk, Francis, Holler, Ernst, Watanaboonyongcharoen, Phandee, Efebera, Yvonne A., Ferrara, James L.M., Panoskaltsis-Mortari, Angela, Weisdorf, Daniel, Lee, Stephanie J., and Pidala, Joseph

Published
2016
Full Text
View/download PDF

39. supplemental figure legend from A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation

Author

Arai, Sally, primary, Pidala, Joseph, primary, Pusic, Iskra, primary, Chai, Xiaoyu, primary, Jaglowski, Samantha, primary, Khera, Nandita, primary, Palmer, Jeanne, primary, Chen, George L., primary, Jagasia, Madan H., primary, Mayer, Sebastian A., primary, Wood, William A., primary, Green, Michael, primary, Hyun, Teresa S., primary, Inamoto, Yoshihiro, primary, Storer, Barry E., primary, Miklos, David B., primary, Shulman, Howard M., primary, Martin, Paul J., primary, Sarantopoulos, Stefanie, primary, Lee, Stephanie J., primary, and Flowers, Mary E.D., primary

Published
2023
Full Text
View/download PDF

40. Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation

Author

Williams, Kirsten M., Cheng, Guang-Shing, Pusic, Iskra, Jagasia, Madan, Burns, Linda, Ho, Vincent T., Pidala, Joseph, Palmer, Jeanne, Johnston, Laura, Mayer, Sebastian, Chien, Jason W., Jacobsohn, David A., Pavletic, Steven Z., Martin, Paul J., Storer, Barry E., Inamoto, Yoshihiro, Chai, Xiaoyu, Flowers, Mary E.D., and Lee, Stephanie J.

Published
2016
Full Text
View/download PDF

43. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia

Author

Churpek, Jane E., Pyrtel, Khateriaa, Kanchi, Krishna-Latha, Shao, Jin, Koboldt, Daniel, Miller, Christopher A., Shen, Dong, Fulton, Robert, O’Laughlin, Michelle, Fronick, Catrina, Pusic, Iskra, Uy, Geoffrey L., Braunstein, Evan M., Levis, Mark, Ross, Julie, Elliott, Kevin, Heath, Sharon, Jiang, Allan, Westervelt, Peter, DiPersio, John F., Link, Daniel C., Walter, Matthew J., Welch, John, Wilson, Richard, Ley, Timothy J., Godley, Lucy A., and Graubert, Timothy A.

Published
2015
Full Text
View/download PDF

45. Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report

Author

Lee, Stephanie J., Wolff, Daniel, Kitko, Carrie, Koreth, John, Inamoto, Yoshihiro, Jagasia, Madan, Pidala, Joseph, Olivieri, Attilio, Martin, Paul J., Przepiorka, Donna, Pusic, Iskra, Dignan, Fiona, Mitchell, Sandra A., Lawitschka, Anita, Jacobsohn, David, Hall, Anne M., Flowers, Mary E.D., Schultz, Kirk R., Vogelsang, Georgia, and Pavletic, Steven

Published
2015
Full Text
View/download PDF

46. Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study

Author

Kitko, Carrie L., primary, Arora, Mukta, additional, DeFilipp, Zachariah, additional, Zaid, Mohammad Abu, additional, Di Stasi, Antonio, additional, Radojcic, Vedran, additional, Betts, Courtney B., additional, Coussens, Lisa M., additional, Meyers, Michael L., additional, Qamoos, Hope, additional, Ordentlich, Peter, additional, Kumar, Vinit, additional, Quaranto, Christine, additional, Schmitt, Aaron, additional, Gu, Yu, additional, Blazar, Bruce R., additional, Wang, Trent P., additional, Salhotra, Amandeep, additional, Pusic, Iskra, additional, Jagasia, Madan, additional, and Lee, Stephanie J., additional

Published
2022
Full Text
View/download PDF

47. Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Author

Schroeder, Mark A., primary, Choi, Jaebok, additional, Atluri, Himachandana, additional, Atkins, Jordan, additional, Harding, Melinda, additional, Eisele, Jeremy, additional, Gao, Feng, additional, Abboud, Ramzi, additional, Abboud, Camille, additional, Cashen, Amanda F., additional, Christopher, Matthew, additional, Fehniger, Todd A., additional, Ferraro, Francesca, additional, Ghobadi, Armin, additional, Jacoby, Meagan A., additional, Pusic, Iskra, additional, Stockerl-Goldstein, Keith E, additional, Uy, Geoffrey L., additional, Vij, Ravi, additional, Walter, Matthew J, additional, Westervelt, Peter, additional, and DiPersio, John F., additional

Published
2022
Full Text
View/download PDF

48. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans

Author

Alsoussi, Wafaa B., primary, Malladi, Sameer K., additional, Zhou, Julian Q., additional, Liu, Zhuoming, additional, Ying, Baoling, additional, Kim, Wooseob, additional, Schmitz, Aaron J., additional, Lei, Tingting, additional, Horvath, Stephen C., additional, Sturtz, Alexandria J., additional, McIntire, Katherine M., additional, Evavold, Birk, additional, Han, Fangjie, additional, Scheaffer, Suzanne M., additional, Fox, Isabella F., additional, Parra-Rodriguez, Luis, additional, Nachbagauer, Raffael, additional, Nestorova, Biliana, additional, Chalkias, Spyros, additional, Farnsworth, Christopher W., additional, Klebert, Michael K., additional, Pusic, Iskra, additional, Strnad, Benjamin S., additional, Middleton, William D., additional, Teefey, Sharlene A., additional, Whelan, Sean P.J., additional, Diamond, Michael S., additional, Paris, Robert, additional, O’Halloran, Jane A., additional, Presti, Rachel M., additional, Turner, Jackson S., additional, and Ellebedy, Ali H., additional

Published
2022
Full Text
View/download PDF

49. Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen

Author

Manjappa, Shivaprasad, Bhamidipati, Pavan Kumar, Stokerl-Goldstein, Keith E., DiPersio, John F., Uy, Geoffrey L., Westervelt, Peter, Liu, Jingxia, Schroeder, Mark A., Vij, Ravi, Abboud, Camille N., Fehniger, Todd A., Cashen, Amanda F., Pusic, Iskra, Jacoby, Meagan, Meera, Srinidhi J., and Romee, Rizwan

Published
2014
Full Text
View/download PDF

50. Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.

Author

Kitko, Carrie L., Arora, Mukta, DeFilipp, Zachariah, Zaid, Mohammad Abu, Di Stasi, Antonio, Radojcic, Vedran, Betts, Courtney B., Coussens, Lisa M., Meyers, Michael L., Qamoos, Hope, Ordentlich, Peter, Kumar, Vinit, Quaranto, Christine, Schmitt, Aaron, Gu, Yu, Blazar, Bruce R., Wang, Trent P., Salhotra, Amandeep, Pusic, Iskra, and Jagasia, Madan

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results